chenodeoxycholic acid has been researched along with Metabolic Syndrome in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 8 (80.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
Authors | Studies |
---|---|
Abraham, DJ; Lin, HR | 1 |
Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
Aguilera, V; Ampuero, J; Bellido, F; Romero-Gómez, M; Sánchez-Torrijos, Y | 1 |
Adinolfi, LE; Lonardo, A; Marrazzo, A; Maurantonio, M; Nascimbeni, F; Rinaldi, L | 1 |
Adorini, L; Cellai, I; Comeglio, P; Filippi, S; Maggi, M; Maneschi, E; Marini, M; Morelli, A; Persani, L; Rastrelli, G; Sarchielli, E; Vannelli, GB; Vignozzi, L | 1 |
Adorini, L; Cellai, I; Comeglio, P; Filippi, S; Galli, A; Maggi, M; Maneschi, E; Mannucci, E; Morelli, A; Rastrelli, G; Saad, F; Sarchielli, E; Vannelli, GB; Vignozzi, L | 1 |
Alawad, AS; Levy, C | 1 |
Costa, SM; Couto, CA; Lisboa, QC | 1 |
Adorini, L; Carini, M; Cellai, I; Comeglio, P; Filippi, S; Gacci, M; Maggi, M; Maneschi, E; Morelli, A; Piccinni, MP; Saad, F; Sarchielli, E; Serni, S; Vannelli, GB; Vignozzi, L | 1 |
Adorini, L; Carini, M; Cellai, I; Comeglio, P; Filippi, S; Gacci, M; Maggi, M; Maneschi, E; Morelli, A; Sarchielli, E; Vannelli, GB; Vignozzi, L; Yehiely-Cohen, R | 1 |
4 review(s) available for chenodeoxycholic acid and Metabolic Syndrome
Article | Year |
---|---|
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
New therapeutic perspectives in non-alcoholic steatohepatitis.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Clinical Trials as Topic; Combined Modality Therapy; Diet, Mediterranean; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Dyslipidemias; Endoscopy; Exercise Therapy; Gastrointestinal Microbiome; Glucagon-Like Peptide-1 Receptor; Humans; Insulin Resistance; MAP Kinase Kinase Kinase 5; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity, Abdominal; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Weight Loss | 2018 |
Nonalcoholic fatty liver disease: Evolving paradigms.
Topics: Biomarkers; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Diagnostic Imaging; Diet, Reducing; Dyslipidemias; Exercise Therapy; Humans; Hyperuricemia; Hypoglycemic Agents; Liver; Liver Function Tests; Liver Neoplasms; Mass Screening; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Assessment; Risk Factors; Vitamin E | 2017 |
FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
Topics: Animals; Azepines; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis; Drug Evaluation, Preclinical; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Indoles; Isoxazoles; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2016 |
6 other study(ies) available for chenodeoxycholic acid and Metabolic Syndrome
Article | Year |
---|---|
Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.
Topics: Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; Chenodeoxycholic Acid; DNA-Binding Proteins; Drug Design; Genes, Reporter; Humans; Metabolic Syndrome; Models, Chemical; Models, Molecular; Neoplasms; Protein Binding; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Transcriptional Activation; Transfection; Two-Hybrid System Techniques | 2006 |
Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits.
Topics: Animals; Antibodies, Monoclonal; Biomarkers; Chenodeoxycholic Acid; Diet, High-Fat; Gene Expression Regulation; Glucose Transporter Type 4; Gonadotropin-Releasing Hormone; Immunohistochemistry; Inflammation; Infliximab; Male; Metabolic Syndrome; Neurons; Preoptic Area; Rabbits; Receptors, G-Protein-Coupled; RNA, Messenger | 2014 |
Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
Topics: Acetylcholine; Animals; Antibodies, Monoclonal; Chenodeoxycholic Acid; Diet, High-Fat; Dietary Fats; Erectile Dysfunction; Fatty Liver; Gene Expression; Humans; Imidazoles; Infliximab; Liver; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Rabbits; Receptors, Cytoplasmic and Nuclear; Sulfones; Testosterone; Triazines; Tumor Necrosis Factor-alpha; Vardenafil Dihydrochloride | 2014 |
Current management of non-alcoholic fatty liver disease.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Diet, Healthy; Exercise; Humans; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease | 2016 |
Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit.
Topics: Androgens; Animals; Biomarkers; Chenodeoxycholic Acid; Dietary Fats; Disease Models, Animal; Drug Evaluation, Preclinical; Estradiol; Fibrosis; Male; Metabolic Syndrome; Prostate; Prostatitis; Rabbits; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Testosterone | 2012 |
Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome.
Topics: Androgens; Animals; Blood Glucose; Cell Movement; Chenodeoxycholic Acid; Cholesterol; Diet, High-Fat; Disease Models, Animal; Hypogonadism; Male; Metabolic Syndrome; Muscle Contraction; Myocytes, Smooth Muscle; Prostate; Rabbits; Receptors, Androgen; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Testosterone; Triglycerides; Triptorelin Pamoate; Urinary Bladder | 2012 |